Investor Presentaiton
Radiopharmaceuticals Business
Industry
Overview (1)
Business
Overview
Products
Strategy
(1)
Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach
US$3.5bn by 2023
Oncology and cardiology diagnosis accounted for 69.4% of the industry in 2017
Increase of cardiovascular, cancerous and neurological diseases are likely to drive molecular imaging
procedures
Specializes in cardiology, pulmonology, oncology and endocrinology as well as bone, brain and renal imaging
Supplies diagnostic and therapeutic radiopharmaceutical products to 18 countries
#3 radiopharmaceutical manufacturer in nuclear medicine industry in the US based on revenue (1)
(US$bn)
Market Size of Industry in North America
CAGR (2013-17): 6.1%
CAGR (2017-23): 6.2%
1.9 2.0 2.2 2.3 2.4 2.6 2.7 2.9 3.0 3.2 3.5
2013
2014
2015
2016
2017E
2018F
2019F
2020F
2021F
2022F
Customers include 3rd party commercial radiopharmacy networks, our radiopharmacies, hospitals, standalone imaging centers and cardiologists
Long-term contracts in place in the US
USFDA approved manufacturing facility at Kirkland, Montreal
MAA for lung perfusion imaging (Sole supplier with 100% market share (¹))
➤ DraxImage® DTPA for lung ventilation and renal imaging ( Sole supplier with 100% market share (¹))
HICONⓇ Sodium lodine-131 solution for thyroid disease and thyroid cancer management (Currently the only FDA
approved supplier of I-131 (Thyroid) in the market)
RUBYⓇ Rubidium Rb-82 Generator and RUBY® Rubidium Elution System (505 (b)(2)products) for myocardial
perfusion imaging with PET
DraxImage Exametazime (505 (b)(2)product) for intra-abdominal infection and inflammatory bowel disease
Planning to file NDA for I-131 mIBG (currently undergoing Phase II and Phase III clinical trials in US) and 505(b)(2)
for 7 other products
Achieve market leadership in the nuclear medicine industry
Increase market share of RUBY-FILL® Generator and RUBY Elution System™M - cardiac PET imaging
Leverage leadership position in existing products
Expand product portfolio through launch of niche and differentiated products
According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the
Global and US Generic Pharmaceutical Industry
2023F
Ruby-Fill® (Rubidium Rb82
Generator and Elution system)
JUBILANT
LIFESCIENCESView entire presentation